We first investigated sotorasib, which is already approved for clinical treatment of KRAS-G12C lung adenocarcinoma, in combination with tipifarnib, an FTi that was recently granted Breakthrough Therapy Designation for treatment of HRAS mutant head and neck squamous cell carcinoma [31]. Here, HRAS is linked to head and neck squamous cell carcinoma.